Abstract: 3beta, 17beta disubstituted steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions.

Abstract: The present invention relates to a process for purification a protein comprising a semi-continuous chromatography step whereby the flow-through is collected and re-loaded onto the chromatography matrix.

Abstract: A system and method for producing high levels of autologous IL-1RA cytokine, includes a blood collection vessel, a cover, a portion of separation gel, an anticoagulant portion, a plasma collection syringe comprising a sharp needle, a buffy coat collection syringe and an incubation tube with cover. The blood collection vessel is adapted such that when containing whole blood and being centrifuged, after treatment yields separation fractions comprising, a first fraction of RBCs sediment, a second fraction of said gel, a third fraction comprising WBCs, platelets and a fourth fraction of plasma solution.

Abstract: The present disclosure provides AAV capsid proteins comprising a modification in the amino acid sequence and virus capsids and virus vectors comprising the modified AAV capsid protein. The disclosure also provides methods of administering the virus vectors and virus capsids of the disclosure to a cell or to a subject in vivo.

Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) G ectodomain are provided. Also disclosed are nucleic acids encoding the RSV G ectodomain and methods of producing the RSV G ectodomain. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for inhibiting a RSV infection in a subject by administering an effective amount of the recombinant RSV G ectodomain to the subject to produce a protective immune response.

Abstract: Provided herein are influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and/or treatment of influenza virus infections.

Abstract: Fusion proteins containing a targeting sequence, an exosporium protein, or an exosporium protein fragment that targets the fusion protein to the exosporium of a Bacillus cereus family member are provided. Recombinant Bacillus cereus family members expressing such fusion proteins are also provided. Genetically inactivated Bacillus cereus family members and recombinant Bacillus cereus family members that overexpress exosporium proteins are also provided. Seeds coated with the recombinant Bacillus cereus family members and methods for using the recombinant Bacillus cereus family members (e.g., for stimulating plant growth) are also provided. Various modifications of the recombinant Bacillus cereus family members that express the fusion proteins are further provided. Fusion proteins comprising a spore coat protein and a protein or peptide of interest, recombinant bacteria that express such fusion proteins, seeds coated with such recombinant bacteria, and methods for using such recombinant bacteria (e.g.

Abstract: Applications of a ZmROA1 protein or substance regulating the content or activity of the ZmROA1 protein are provided. The ZmROA1 protein can be specified as follows: A1), A2) or A3): A1, the amino acid sequence is the amino acid sequence shown in SEQ ID NO: 3; A2, the protein, which is obtained by replacing and/or deleting and/or adding the amino acid sequence shown in SEQ ID NO: 3 through amino acid residues, is more than 80% identity to A1) and relates to plant root angle; A3, the fusion protein which is obtained by linking N-end or/and C-end of A1) or A2) to protein tags. ZmROA1 protein and its related biological materials can be used to regulate plant density tolerance and/or root angle, and the cultivation of new density-tolerant maize varieties, which helps improve maize harvest index for high and stable yield.

Abstract: The present invention relates to a bee venom-purifying method comprising a virus clearance process and a composition for preventing or treating inflammatory disease by using same, the method comprising the steps of: (a) preparing a bee venom solution containing bee venom; (b) adjusting the pH of the bee venom solution prepared in step (a) into 2.0 to 4.0 by acid treatment to primarily deactivate viruses; and (c) filtering the pH-adjusted bee venom solution of step (b) through a nanofilter of 10 to 20 nm to secondarily remove viruses.

Abstract: The disclosure pertains to conformational epitopes in A-beta, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

Abstract: The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-muscle-specific kinase (MuSK) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells comprising the CAAR.

Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD- L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.

Abstract: The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.

Abstract: The authors of the present invention designed a new fluorescent fusion polypeptide comprising a membrane localization peptide, a peptide capable of binding G-protein or tyrosine receptors following phosphorylation of these receptors by GRKs or RTKs, a vesicularization peptide and a fluorescent peptide. This biosensor is formed by two peptides targeted to two different cellular compartments, allowing the detection of the translocation of GRKs (G-protein receptor kinases) and/or beta-arrestin or Receptor tyrosine kinases (RTKs) from the cell cytoplasm to the cell cytoplasmic membrane in vivo by monitoring the distribution of the fluorescent polypeptide within the cellular cytoplasm.

Abstract: Provided is a method capable of producing a protein at a high level using a cultured animal cell, comprising culturing a cell that expresses APES (Antibody Production Enhancing Sequence) and into which a DNA encoding a desired polypeptide has been introduced, thereby producing the desired polypeptide. APES contains a nucleotide sequence related to nuclear factor ?B inhibitor ? (NfkBia) and has a function of decreasing the intracellular expression of NfkBia.

Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) binding to CD22 and CD3 are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of CD22.

Abstract: Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes TIGIT. Also provided are methods of making and using these constructs.

Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.

Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.

Abstract: Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets.

Abstract: The present invention relates to an anti-CD40 antibody binding specifically to CD40 and use thereof and, particularly, provides an anti-CD40 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same antibody or fragment as an effective ingredient for prevention and/or treatment of cancer, cancer metastasis, infection, and/or immune deficiency diseases.

Abstract: CD38 is expressed on malignant plasma cells. CD28 is a costimulatory molecule required for T-cell activation and survival. Provided herein are novel anti-CD38 antibodies, anti-CD28 antibodies, and bispecific antibodies (bsAbs) that bind to both CD38 and CD28 and act as costimulatory agents to activate T cells via binding CD80 and/or CD86. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD38. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced CD38-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma, lymphoma, and leukemia.

Abstract: The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment and tolerance.

Abstract: It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Abstract: Methods and kits for purifying protein-nanoparticle conjugates are provided. In some embodiments, a multimodal medium having a size exclusion mode and a capture mode is used to purify the protein-nanoparticle conjugates.

Abstract: Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

Abstract: Provided are a novel peptide, a polynucleotide encoding the peptide, an expression vector including the polynucleotide, and a pharmaceutical composition including the peptide, a quasi-drug composition including the peptide, and a health functional food composition including the peptide.

Abstract: The present invention relates to new peptides comprising an amino acid sequence LL-[X]n-LL, wherein X is selected from R, L and W, and n=10 to 12, and wherein [X]n comprises 4 R, 4 L and between 2 and 4 W, that may be used as cell-penetrating peptides. The present invention also relates to nanoparticles comprising a peptide of the invention and a cargo molecule and uses thereof.

Abstract: The invention relates to a method for producing a low-viscosity cellulose ether product, and to the use thereof.

Abstract: Nanocellulose containing a sulfuric acid group and/or a sulfo group, each of which is derived from a sulfuric acid treatment, and an anionic functional group derived from a hydrophilization treatment. The total amount of the sulfuric acid group and/or the sulfo group and the anionic functional group is more than 0.1 mmol/g and not more than 4.0 mmol/g. Also disclosed is a product including a mixture containing the nanocellulose and a method for producing the nanocellulose.

Abstract: The present invention provides a process for producing a nanocellulose material, comprising: fractionating a lignocellulosic biomass feedstock in the presence of a solvent for lignin and water, but no acid catalyst, to generate cellulose-rich solids; and then mechanically treating the cellulose-rich solids to form a nanocellulose material comprising cellulose nanofibrils and/or cellulose nanocrystals. Many organic or inorganic solvents are possible. In some embodiments, the solvent for lignin is an oxygenated organic compound, such as a C1-C18 alcohol, e.g. ethanol, ethylene glycol, propanol, propanediol, glycerol, butanol, or butanediol. The solvent for lignin may be an aromatic alcohol, such as phenol, cresol, or benzyl alcohol. The solvent for lignin may be a ketone, an aldehyde, or an ether, such as methyl ethyl ketone or diethyl ether. The solvent for lignin may be a non-oxygenated alkane, olefin, or aromatic hydrocarbon. In some embodiments, the solvent for lignin is an ionic liquid.

Abstract: Provided are NCC-based materials, as superb barrier materials for preventing oxygen and humidity from penetrating therethrough.

Abstract: Amylopectin potato starch with improved stability against retrogradation and improved freeze and thaw stability, wherein it contains more than 99% amylopectin, preferably 100% amylopectin, is disclosed, as well as a method for the production of a potato (Solanum tuberosum) containing said amylopectin potato starch, wherein said method involves homology-directed mutagenesis using CRISPR/nuclease technology and comprises the following steps: a) provision of potato cells or potato tissue containing potato cells, b) introduction into the nuclei of said potato cells of one or more CRISPR/nuclease complexes each comprising a specific targeting ribonucleotide sequence which is fully or essentially homologous to a target nucleotide sequence located in a DNA sequence immediately upstream of a PAM (5?-NGG-3?protospacer adjacent motif) in a gene coding for a GBSS enzyme and optionally also in a gene coding for an SSII enzyme and/or in a gene coding for an SSIII enzyme, wherein said mutagenesis takes place in one or m

Abstract: The disclosure relates to a method for producing a propylene copolymer, comprising extruding a molten propylene copolymer and a composition essentially comprising at least one peroxydicarbonate and at least one organic peroxide. Extruding is performed by extruding the propylene copolymer, adding the composition to the propylene copolymer, and melt extruding the propylene copolymer in the presence of the composition.

Abstract: The polyethylene according to the present disclosure has a short relaxation time and a uniform particle size, thereby preparing a chlorinated polyethylene excellent in chlorination productivity and glass transition temperature by reacting with chlorine. And, a PVC composition with improved impact strength may also be prepared by including the same.

Abstract: The present invention relates to a method for producing an ethylene-based copolymer, and more particularly, to a method for producing an ethylene-based copolymer capable of increasing process efficiency by preventing plugging and corrosion of a facility. The method for producing an ethylene-based copolymer includes a producing mode and a washing mode of which one is selectively performed. The producing mode includes: a) hyper-compressing primary compressed ethylene, and a mixture including a carboxylic acid-containing comonomer and a polar solvent to produce a compressed material; b) reacting the compressed material to produce a reaction product including an ethylene-based copolymer; and c) separating and recovering unreacted residues from the reaction product and introducing the unreacted residues into the mixture of step a). The washing mode includes: re-supplying the compressed material produced in step a) to step a) as a mixture, without performing step b).

Abstract: Propylene and alpha olefin random copolymers are disclosed that have excellent flow characteristics. For instance, the copolymers can be formulated so as to have a melt flow rate of greater than about 45 g/10 min. While still retaining the above flow characteristics, the copolymer can also be formulated to have greater stiffness, low xylene soluble content, and excellent transparency characteristics especially when combined with one or more clarifying agents.

Abstract: An object of the present invention is to provide a novel ethylene/?-olefin/non-conjugated polyene copolymer containing a certain non-conjugated polyene such as VNB as a copolymerization component, having a low long-chain branching content, excellent in cure characteristics in the case of crosslinking by using peroxide, and having good processability. The ethylene/?-olefin/non-conjugated polyene copolymer according to the present invention has constitutional units derived from ethylene (A), an ?-olefin (B) having 3 to 20 carbon atoms, and a non-conjugated polyene (C) having a total of two or more partial structures selected from the group consisting of the following general formulas (I) and (II) in a molecule, and satisfies certain requirements.

Abstract: An ethylene/tetrafluoroethylene copolymer satisfying the following formula (1): 75? tan ?(60)/tan ?(5)×100?225??(1) wherein peak intensities, determined by Fourier transform infrared spectroscopy, of vibrations derived from a —CF2H group, a —CF2CH2COF group, a —COF group, a —COOH group, a dimer of a —CF2COOH group and a monomer of a CF2CH2COOH group, a —COOCH3 group, a —CONH2 group, and a —CH2OH group satisfy the following formula (2): PIA/(PIB+PIC+PID+PIE+PIF+PIG+PIH)?0.60??(2) wherein the loss tangents (tan ?) and peak intensities (PI) are as defined herein.

Abstract: Novel copolymers that are fluoropolymers including a first repeat unit that is fluorinated and cyclic and a second repeat unit from a trifluorovinyl methylene ether monomer having sulfur or sulfone functionality in the pendant group are disclosed. The copolymers have relatively high gas permeability as a result of a cyclic repeat unit in the copolymer backbone and ionomers from oxidation of the sulfur containing functionality are particularity useful in the cathode structure of a proton exchange membrane fuel cell.

Abstract: A composition includes at least one siloxy-based (meth)acrylate monomer or prepolymer, at least one additional methacrylate monomer, UV, and Visible light blocking agents and one or more crosslinking agents. The final product results in a highly wettable material that possesses physical properties such as a low modulus of elasticity and high oxygen permeability without the need for a non-reactive solubilizing agent and that are free of cyclic and linear siloxanes.

Abstract: A preparation method of an expansive polymer grouting material for treating high-pressure large-flow-rate karst water inrush includes: 1) adding a crosslinking agent to acrylic acid; then adding a polymer water-absorbent resin comonomer and performing a polymerization reaction to obtain a precursor; 2) adding an initiator to the precursor obtained in step 1), heating the mixture, performing a reaction to obtain a hydrogel, and grinding the hydrogel to obtain a primary polymer water-absorbent resin; 3) spraying a surface crosslinking agent onto a surface of the primary polymer water-absorbent resin obtained in step 2), and drying the product; and 4) preparing a suspension from an inorganic water conducting agent, spraying the suspension onto the product obtained in step 3), and performing drying to obtain the expansive polymer grouting material.

Abstract: Pressure sensitive adhesive compositions are disclosed comprising acrylic emulsions that are emulsion polymerization products of (a) a monomer mixture comprising, based on the total weight of monomers in the monomer mixture, from 50 to 99 weight percent 2-ethylhexyl acrylate and from 1 to 50 weight percent an unsaturated monomer, (b) a surfactant, and (c) an initiator. Methods for preparing pressure sensitive adhesive compositions are also disclosed. Food contact articles comprising the disclosed pressure sensitive adhesive compositions are also disclosed. In some embodiments, the disclosed food contact articles have an overall migration of less than 25 mg/dm2, as measured in accordance with EN 1186, or less than 10 mg/dm2, as measured in accordance with EN 1186.

Abstract: Provided is a method of preparing an acrylonitrile-based copolymer for a carbon fiber, which comprises: preparing a reaction solution including a monomer mixture comprising a sulfonate-based monomer represented by Chemical Formula 1, a carboxylic acid-based monomer, and an acrylonitrile-based monomer and an organic solvent; and subjecting the reaction solution to polymerization, wherein the monomer mixture comprises the sulfonate-based monomer represented by Chemical Formula 1 at 0.55 to 1.6 mol %.

Abstract: Polymerizable liquids for 3D printing applications are described herein which, in some embodiments, impart flame resistant and/or flame retardant properties to articles printed from the build materials. The polymerizable liquids may also impart desirable mechanical properties to the articles. In some embodiments, a polymerizable liquid comprises a curable isocyanurate component in an amount of at least 20 wt. %, based on total weight of the polymerizable liquid, and an organophosphate component comprises one or more organophosphate compounds. In some embodiments, the polymerizable liquid further comprises an acrylate component.

Abstract: An object of the present invention is to provide a novel photosensitive resin precursor that can be developed with an alkali and ring-closed even at low temperatures, and preferably has excellent thermal properties and excellent electric properties after curing, and also to provide a use application thereof. As means for achieving the object, disclosed are a bismaleimide compound comprising, in one molecule, two partial structures in each of which a carbon atom having a substituent represented by the following formula (A) (wherein Y represents a direct bond or a divalent linking group), and a carbon atom having a hydroxy group are directly bonded to each other, a polymer which is a self-polymer of the bismaleimide compound, and a benzoxazole which is an intramolecular dehydrated ring-closed product of the polymer.

Abstract: A molded bale of a rubber composition, containing: a rubber-like polymer (A) having an iodine value of 10 to 250, 3% by mass or more of an ethylene structure, and less than 10% by mass of a vinyl aromatic monomer block; and titanium (C), in which a content of the titanium (C) is 3 ppm or more and 120 ppm or less, and a content of aluminum (B) is less than 2 ppm.

Abstract: The invention relates to highly filled urethane systems, methods of making the urethane systems, and their use in commercial applications. More particularly, the invention includes urethane systems with a substantial amount of mineral filler that have acceptable cure kinetics and mechanical properties. The urethane systems include an isocyanate component, a polyol component, and a mineral filler that, in certain embodiments, is selected from talc, mica, calcium carbonate and mixtures or blends thereof.